MetaVia reported on November 5, 2026 that DA-1726, a weekly injection acting on GLP-1 and glucagon receptors, lowered liver fat 68% versus placebo after 16 weeks. The MRI substudy had 12 treated and 4 placebo participants, all otherwise healthy adults with obesity. It is an interim company release. It does not show that DA-1726 treats fatty liver disease.
Ask PeptideBlog about any peptide
What was measured
Part 3B of the phase 1 trial was a 16-week, randomized, placebo-controlled study. DA-1726 was titrated from 16 mg to 32 mg to a 64 mg weekly target by subcutaneous injection. The interim set has 15 treated and 4 placebo participants, and the MRI liver-fat substudy has 12 and 4. The company release was published November 5 after an oral presentation on November 4 at the Precision Liver Symposium. Full Part 3A and 3B data are expected in the first quarter of 2027.

Doses and schedule reported
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Setting | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|
| Phase 1 Part 3B, healthy adults with obesity | Subcutaneous injection | Titrated 16 mg, then 32 mg, to a 64 mg target | Weekly | 16 weeks | Company-reported human trial (interim release) |
No other dosing information was identified, and no dose of DA-1726 has been established as safe or effective for any use.
Results at day 109
| Measure at Day 109 | DA-1726 | Versus placebo |
|---|---|---|
| Liver fat (MRI-PDFF) | Mean baseline 5.2% | 68% lower, geometric mean ratio 0.32, p<0.001; absolute difference -6.4 percentage points |
| Participants with 30% or more relative liver-fat drop | 10 of 12 | 0 of 4 |
| Body weight | -11.9% from baseline | -13.5% placebo adjusted |
| HbA1c | 5.79% to 5.33% | -0.24 percentage points, p=0.006 |
| Total lean tissue and thigh muscle volume | 8% and 9% lower |
What the numbers do and do not show
Most of these participants had little liver fat to lose. Mean baseline liver fat in the treated group was 5.2%, right at the usual 5% threshold for steatosis, and only 5 of the 12 treated participants were above it. All five fell below 5%, from a mean of 8.3% to 3.0%. That is a real result, in five people.
The 68% is a ratio against placebo, and the placebo group moved the other way: its liver fat rose 40.4% from its own baseline, and it started higher (8.0%). If the ratio is built on changes relative to placebo, the treated group’s own fall would be smaller than 68%, and the release gives no within-arm figure or confidence interval for liver fat. Four placebo participants is a very small anchor for any ratio.
Two further limits. First, these are otherwise healthy adults with obesity, not people with MASH, MetALD or alcohol-associated liver disease, so statements about those conditions are extrapolation. MRI-PDFF is a surrogate, and no biopsy was done. Second, the lean figures do not support “preserved” without qualification: total lean tissue was 8% lower and thigh muscle volume 9% lower than placebo, against 19% to 22% lower adipose tissue. The release does not define the MRI method or give absolute volumes. The detail sits in the muscle article.
Tolerability: gastrointestinal events occurred in 9 of 15 treated participants, with vomiting in 7 (46.7%). One serious adverse event of severe vomiting was considered possibly related, and the participant recovered. No one stopped because of a gastrointestinal event. “No new gastrointestinal events after week 9” describes new onset, not total burden.
For context
The better-powered liver-fat comparison is retatrutide’s phase 2 substudy of 98 people who all had at least 10% liver fat at entry, covered on the retatrutide entry. Different drug, different population and different design, so no ranking.
What comes next
Full data are due in Q1 2027, and MetaVia plans a 48-week, non-biopsy phase 2 in up to 150 people with MetALD or alcohol-associated liver disease, targeted for the second half of 2027. Registry record for the first-in-human study: NCT06252220.
Frequently asked questions
What did the DA-1726 liver fat substudy find? MetaVia reported liver fat (MRI-PDFF) 68% lower than placebo at day 109, in an MRI substudy of 12 treated and 4 placebo participants.
Does it show DA-1726 treats fatty liver disease? No. Participants were otherwise healthy adults with obesity, not people with MASH or alcohol-associated liver disease, and MRI-PDFF is a surrogate marker, not a biopsy outcome.
What does the 68% mean? It is a ratio against placebo (geometric mean ratio 0.32). The placebo group moved the other way, so the figure is not the treated group’s own fall in liver fat.
Did DA-1726 preserve muscle? Not shown. Total lean tissue was 8% lower and thigh muscle volume 9% lower than placebo, against 19% to 22% lower adipose tissue.
What dose was used? A weekly subcutaneous injection titrated from 16 mg to 32 mg to a 64 mg target over 16 weeks. This is what the trial administered, not advice.
When will full data be available? The company expects full Part 3A and 3B data in the first quarter of 2027.
Sources
| Source | Organization | Date | Category |
|---|---|---|---|
| MetaVia announces statistically significant 68% reduction in liver fat | MetaVia | 2026-11-05 | Sponsor press release |
| NCT06252220 first-in-human study record | ClinicalTrials.gov | Registry record | Clinical registry |
Related reading: GLP-1 drugs and muscle loss and the retatrutide entry.